Canonical: https://ownershiptrace.com/13f/companies/6730

# Who owns Edesa Biotech, Inc. (EDS)? Elite investor 13F holders

1 tracked elite investors reported holding Edesa Biotech, Inc as of 2026-06-30, including Rubric Capital. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

1 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Rubric Capital](https://ownershiptrace.com/13f/investors/120) | Common Shares, no par value per share | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 5443035.00 USD | 669500.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1687509/0001104659-26-097098-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)